


## REMARKS

Entry of the instant amendment and examination of the above-identified application on merits as amended is respectfully requested.

Claims 1-27 were presented for examination.

Restriction to one of the following inventions has been required under 35 U.S.C. §121:

Group 1) An antagonist having the chemical structure:



wherein:

A is imidazole, pyrazole, or triazole;

R is  $-C(X)R^1$ ,  $-C(X)-N(R^1)_2$ ,  $-C(X)OR^1$ ,  $-C(X)SR^1$ ,  $-SO_nR^1$ ,  $-SO_nSR^1$  or  $-SO_n-N(R^1)_2$ ;

$R^1$  is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, heterocyclic, lower alkenyl, lower alkanoyl, or, if linked to a nitrogen atom, then taken together with the nitrogen atom, forms an azetidine ring or a 5-6 membered heterocyclic ring containing one or more heteroatoms;

$R^2$  is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;


$R^3$  is furan, pyrrole, thiophene, benzofuran, benzopyrrole, benzothiophene, optionally substituted with one or more substituents selected from the group consisting of hydroxy, acyl, alkyl, alkoxy, alkenyl, alkynyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, amino, substituted amino, aminoacyl, acyloxy, acylamino, alkaryl, aryl, substituted aryl, aryloxy, azido, carboxyl,

carboxylalkyl, cyano, halo, nitro, heteroaryl, heteroaryloxy, heterocyclic, heterocyclooxy, aminoacyloxy, thioalkoxy, substituted thioalkoxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO<sub>2</sub>-alkyl, -SO<sub>2</sub>-substituted alkyl, -SO<sub>2</sub>-aryl, -SO<sub>2</sub>-heteroaryl, and trihalomethyl;

X is O, S, or NR<sup>1</sup>; and

pharmaceutically acceptable salts thereof.

Group 2) An antagonist having the chemical structure:



wherein:

A is imidazole, pyrazole, or triazole;

R<sup>2</sup> is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;

R<sup>3</sup> is furan; and

R<sup>6</sup> is aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle; and

pharmaceutically acceptable salts thereof.

In response thereto, Applicants provisionally elect the invention directed to compounds in Group 1, i.e., original claims 6, 8, 9 and 10, with traverse.

It is respectfully submitted that compounds in Group 1 and Group 2 are not independent or distinct species having a different chemical formula. The compounds in Group 2 are all encompassed by the scope of Group 1, i.e., compounds in Group 2 correspond to compounds in Group 1 wherein R is -C(X)-N(R<sup>1</sup>)<sub>2</sub> in which X is O, and one of the R<sup>1</sup> substituents is hydrogen and the other has a meaning as defined for R<sup>6</sup>, a subgroup of compounds within the definition of R<sup>1</sup> in Group 1.

In view of the above, claims 1-5 have been withdrawn.

Claim 6 has been rewritten in independent form.

Claim 6 has also been amended to more accurately claim certain aspects of the instant invention. The specification has been amended accordingly.

Claims 7 and 11-12 have been amended to depend from claim 6. Furthermore, claim 7 has been amended to correct obvious clerical errors.

Claims 8-10 and 13-16 are as originally filed.

Claims 17 and 22-27 have been cancelled.

Claim 18 has been amended to correct obvious clerical errors.

Claims 19-21 have been amended to correct an obvious error in the claim dependency.


New claims 28-31 have been added to more adequately claim certain aspects of the instant invention.

It is respectfully submitted that the subject matter of the instant claims is fully supported by the enabling disclosure of the instant application, and no new subject matter has been incorporated by the above amendments.

In view of the foregoing, all the instant claims 6-16, 18-21 and 28-31 are directed to a single invention, and believed to be in condition for allowance and such is earnestly solicited.

It is estimated that no fees are required for filing this Amendment. Notwithstanding, if a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to King Pharmaceuticals Deposit Account No. 50-3706.

Respectfully submitted,



---

Paivi Kukkola  
Agent for Applicant  
Reg. No. 50,499

King Pharmaceuticals, Inc.  
7 Roszel Road, Fifth Floor  
Princeton, NJ 08540  
Tel: (609) 580-8964

Date: April 5, 2006